Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex
Status:
Recruiting
Trial end date:
2021-11-20
Target enrollment:
Participant gender:
Summary
There had been much evidence in aspirin controlling tumorous conditions conducted by basic
researches, especially through mammilian target of rapamycin (mTOR) pathway. The investigator
observed efficacy of aspirin in the treatment of tuberous sclerosis complex (TSC) in one
child who got Kawasaki disease and in the addition four TSC patients with epilepsy. The
investigator intend to evaluate whether aspirin would be an effective add-on treatment in TSC
patients with refractory seizures.
Phase:
Phase 2
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborators:
Shijiazhuang Pharmaceutical Group Co. Ltd. Shijiazhuang Yiling Pharmaceutical Co. Ltd